Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Salofalk 1g/actuation Rectal Foam

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Mesalazine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Mesalazine
Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for Salofalk rectal foam contains the active substance mesalazine, an anti-inflammatory agent used to treat inflammatory bowel disease. Salofalk rectal foam is used for the treatment of: –

Inflammation of the large intestine (colon) and rectum (back passage) known by doctors as ulcerative colitis.

What you need to know before you take it

e Salofalk rectal foam Do not use Salofalk rectal foam If you are allergic to mesalazine, to salicylic acid, to salicylates such as as acetylsalicylic acid (e.g., Aspirin®) or to any of the other ingredients of Salofalk rectal foam (listed in section 6) If you have a serious liver or kidney disease. Warnings and precautions Before you start using this medicine you should tell your doctor –

If you have a history of problems with your lungs, particularly if you suffer from bronchial asthma. If you have a history of allergy to sulphasalazine, a substance related to mesalazine. If you suffer with problems of your liver. If you suffer with problems of your kidney. If you have ever developed a severe skin rash or skin peeling, blistering and/or mouth sores after using mesalazine.

Mesalazine may produce red-brown urine discoloration after contact with sodium hypochlorite bleach in the toilet water. It concerns a chemical reaction between mesalazine and bleach and is harmless. Further precautions: During treatment your doctor may want to keep you under close medical supervision, and you may need to have regular blood and urine tests. Kidney stones may develop with use of mesalazine. Symptoms may include pain in sides of abdomen and blood in urine. Take care to drink sufficient amount of liquid during treatment with mesalazine. Serious skin reactions including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) have been reported in association with mesalazine treatment. Stop using mesalazine and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4.

If you experience strong or recurrent headache, disturbed vision, or ringing or buzzing in the ears contact your doctor immediately. Other medicines and Salofalk rectal foam Please tell your doctor if you take or use any of the medicines mentioned below, as the effects of these medicines may change (interactions): Certain agents that inhibit blood clotting (medicines for thrombosis or to thin your blood, e.g. warfarin). Azathioprine, 6-mercaptopurine or thioguanine (medicines used to treat immune disorders). Tell your doctor or pharmacist if you are taking or have recently taken or might take any other medicines, including medicines obtained without a prescription. It may still be all right for you to use Salofalk rectal foam and your doctor will be able to decide what is suitable for you. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should only use Salofalk rectal foam during pregnancy if your doctor tells you to. You should also only use Salofalk rectal foam during breast-feeding if your doctor tells you to, as this medicine may pass into breast milk. Driving and using machines There are no effects on the ability to drive and use machines. Salofalk rectal foam contains propylene glycol, sodium metabisulphite and cetostearyl alcohol This medicine contains 3.44 g propylene glycol in each actuation of Salofalk rectal foam, which may cause skin irritation. Sodium metabisulphite may rarely cause severe hypersensitivity reactions and bronchospasm (can be experienced in the form of breathing problems). Cetostearyl alcohol may cause local skin reactions (e.g. contact dermatitis).

How to take it

Salofalk rectal foam Always use Salofalk rectal foam exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

Method of administration: This medicine may only be used rectally, so it has to be inserted through the anus. It is not intended to be taken by mouth. Do not swallow. Dosage: Dose for adults: The usual dose is 2 spray actuations once a day at bedtime. If you have difficulty retaining this amount of foam, it may also be administered in two separate doses: one at bedtime and the other during the night or early in the morning (after excreting the first dose). Emptying your bowels before using Salofalk rectal foam produces the best results. Use in children: Salofalk rectal foam should not be used in children because there is little experience and only limited documentation for an effect in children. Preparing to use the foam Store and use Salofalk rectal foam at room temperature (between 20 and 30°C). Do not refrigerate or freeze. Also see section 5. Push the applicator firmly onto the spout of the spray can. Shake the spray can for about 20 seconds to mix the contents.

Before first use, remove the safety lock (plastic flap) from under the pump dome.

Twist the dome on the top of the spray can until the semi-circular gap underneath is in line with the applicator. The spray can is now ready for use.

Using the foam

Place your index finger on the top of pump dome and turn the can upside down. Note that the spray can will only work properly when held with the pump dome pointing down.

Stand with one foot on a stool or chair or lie on your side with the lower leg stretched out and the upper leg bent for balance. Insert the applicator into your rectum as far as possible. Push the pump dome down fully once and then slowly release it – the foam comes out of the spray can when you release the dome. To administer the second spray, push the dome again and release slowly. Keep the applicator in place for 10-15 seconds before taking it out. This ensures the full dose is delivered into the rectum and no foam is spilt.

After administering the foam, remove the applicator and dispose of it with your household waste in the plastic bag provided. Use a new applicator for the next administration.

• •

Wash your hands and try not to empty your bowels until the next morning. If you go to hospital or see another doctor, tell them you are using this medicine.

Use Salofalk rectal foam regularly and consistently to achieve the desired effect. Duration of treatment How long you will use the medicine depends upon your condition. Your doctor will decide how long you are to continue the medication. Mild acute episodes of inflammatory bowel disease (ulcerative colitis) generally subside after 4-6 weeks. If long-term treatment is required, your doctor will prescribe you an oral form of mesalazine, e.g. Salofalk granules. If you think that the effect of Salofalk rectal foam is too strong or too weak, talk to your doctor. If you use more Salofalk rectal foam than you should Contact a doctor if you are in doubt so he or she can decide what to do. If you use too much Salofalk rectal foam on one occasion, just take your next dose as prescribed. Do not use a smaller amount. If you forget to use Salofalk rectal foam Do not take a larger than normal dose of Salofalk rectal foam next time, but continue treatment at the prescribed dosage. If you stop using Salofalk rectal foam Do not stop using this product until you have talked to your doctor. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

Possible side effects

Like all medicines, Salofalk rectal foam can cause side effects, although not everybody gets them. If you experience any of the following symptoms after using this medicine, you should contact your doctor and stop using Salofalk rectal foam immediately:

  • General allergic reactions such as skin rash, fever, joint pain and/or breathing difficulties or a general inflammation of your large bowel (causing severe diarrhoea and abdominal pain). These reactions are very rare.
  • A marked reduction of your general health, especially if accompanied by fever, and/or a sore throat and mouth. These symptoms can, very rarely, be due to a fall in the number of white cells in your blood, which may make you more prone to developing a serious infection (agranulocytosis). Other cells of the blood may also be affected (e.g. platelets or red cells causing aplastic anaemia or thrombocytopenia) and cause symptoms which may include unexplained bleeding, purple spots or patches under your skin, anaemia (feeling tired, weak and looking pale, especially on lips and nails). A blood test can confirm whether your symptoms are due to an effect of this medicine on your blood. These reactions are very rare.
  • Serious skin rashes with reddish non-elevated, target-like or circular patches on the trunk, often with central blisters, skin peeling, ulcers of mouth, throat, nose, genitals and eyes, widespread rash, fever and enlarged lymph nodes. These can be preceded by fever and flu-like symptoms. These reactions occur in an unknown number of patients (frequency not known).
  • Shortness of breath, chest pain or irregular heartbeat, or swollen limbs which may be indicative of cardiac hypersensitivity reactions. These reactions are rare.
  • Problems with your kidney function (can occur very rarely), e.g. a change in the colour or amount of urine produced and swollen limbs or a sudden flank pain (caused by a kidney stone) (occur in an unknown number of patients (frequency not known)).
  • Strong or recurrent headache, disturbed vision, or ringing or buzzing in the ears.

These could be symptoms of increased pressure within your skull (idiopathic intracranial hypertension) (frequency not known [cannot be estimated from the available data]). The following side effects have also been reported by patients using mesalazine: Common: may affect less than 1 in 10 patients Abdominal discomfort. Rash, itching Uncommon: may affect less than 1 in 100 patients Anal discomfort, anal irritation and painful urgent need to empty the bowels. Rare: may affect less than 1 in 1,000 patients Abdominal pain, diarrhoea, wind (flatulence), nausea and vomiting Headache, dizziness Increased sensitivity of your skin to sun and ultraviolet light (photosensitivity) Very rare: may affect less than 1 in 10,000 patients Severe abdominal pain, because of acute inflammation of the pancreas Shortness of breath, cough, wheezing, lung shadow on x-ray due to allergic and/or inflammatory lung conditions Muscle and joint pain Jaundice or abdominal pain because of liver and bile flow disorders Hair loss and the development of baldness Numbness and tingling in the hands and feet (peripheral neuropathy) Reversible decrease in semen production Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system: Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store By reporting side effects, you can help provide more information on the safety of this medicine.

How to store it

Salofalk rectal foam Keep this medicine out of the sight and reach of children. Do not use Salofalk rectal foam after the expiry date which is stated on the carton and the spray can. The expiry date refers to the last day of that month. The contents of the container must be used within 12 weeks after first opening.

Do not store above 30°C. Do not refrigerate or freeze. Note: foam may cause staining. The container is pressurised and contains 3.75% by weight of flammable propellant. Protect from sunlight and temperatures over 50°C. Do not force open, pierce or burn empty containers, even after use. Do not spray near a flame or incandescent material. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

Contents of the pack and other information

What Salofalk rectal foam contains The active substance of Salofalk rectal foam is mesalazine and each spray actuation contains 1 g of mesalazine. The other ingredients are sodium metabisulphite (E223), disodium edetate, cetostearyl alcohol, polysorbate 60, propylene glycol and propane, n-butane, isobutane as propellants. What Salofalk rectal foam looks like and contents of the pack Salofalk rectal foam is a white-greyish to slightly reddish-violet and creamy firm foam. Salofalk rectal foam is available in packs containing 1 spray can and 14 applicators and as a bundle pack. A bundle pack consists of 4 packs containing 1 spray can and 14 applicators each. Each spray can of Salofalk rectal foam contains 80 grams of foam, which is sufficient for 14 spray actuations (equivalent to 7 doses). Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Dr. Falk Pharma GmbH Leinenweberstr. 5 79108 Freiburg Germany Tel.: +49 (0) 761 / 1514-0 E-mail: [email protected] Salofalk rectal foam is authorised in the Member States of the EEA under the following name: Austria, Denmark, Finland, Germany, Great Britain, Greece, Ireland, Luxembourg, The Netherlands, Norway, Portugal, Spain and Sweden: Salofalk® This leaflet was last revised in 01/2025. Marketing authorisation number: PL 08637/0003

Frequently asked questions about Salofalk 1g/actuation Rectal Foam

What is the active substance in Salofalk 1g/actuation Rectal Foam?

The active substance in Salofalk 1g/actuation Rectal Foam is mesalazine.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Salofalk 1g/actuation Rectal Foam, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Salofalk 1g/actuation Rectal Foam without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Mesalazine (31 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

Treatment of active, mild ulcerative colitis of the sigmoid colon and rectum.

4.2. Posology and method of administration

Adults and elderly:

Two administrations once a day at bedtime. Salofalk rectal foam should be used at room temperature (between 20°C and not more than 30°C; see also section 6.4. The canister is first fitted with an applicator and then shaken for about 20 seconds before the applicator is inserted into the rectum as far as comfortable. To administer a dose of Salofalk, the pump dome is fully pushed down and released. Note that the spray will only work properly when held with the pump dome pointing down. Following the first or second activation depending upon need (see below) the applicator should be held in position for 10-15 seconds before being withdrawn from the rectum. If the patient has difficulty in holding this amount of foam, the foam can also be administered in divided doses: one at bedtime and the other during the night (after evacuation of the first single dose) or in the early morning. The best results are obtained when the intestine is evacuated prior to administration of Salofalk rectal foam.

In general, an acute episode of a mild ulcerative colitis subsides after 4-6 weeks. It is recommended to continue the maintenance therapy with an oral mesalazine preparation e.g., Salofalk prolonged release granules at a dosage recommended for this preparation.

Paediatric population:

There is little experience and only limited documentation for an effect in children.

Duration of treatment

The duration of use is determined by the physician.

Method of Administration

rectal.

4.3. Contraindications

Salofalk is contraindicated in cases of:

- known hypersensitivity to salicylates or to any of the excipients listed in section 6.1

- severe impairment of hepatic or renal function

Caution:

Asthmatics should be treated with care with Salofalk since sulphite contained in the foam may cause hypersensitivity reactions.

4.4. Special warnings and precautions for use

Blood tests (differential blood count; liver function parameters such as ALT or AST; serum creatinine) and urinary status (dip sticks) should be determined prior to and during treatment, at the discretion of the treating physician. As a guideline, follow-up tests are recommended 14 days after commencement of treatment, then a further two to three tests at intervals of 4 weeks.

If the findings are normal, follow-up tests should be carried out every 3 months. If additional symptoms occur, these tests should be performed immediately.

Caution is recommended in patients with impaired hepatic function.

Mesalazine should not be used in patients with impaired renal function.

Mesalazine-induced renal toxicity should be considered if renal function deteriorates during treatment. If this is the case, Salofalk rectal foam should be discontinued immediately.

Cases of nephrolithiasis have been reported with the use of mesalazine including stones with a 100% mesalazine content. It is recommended to ensure adequate fluid intake during treatment.

Mesalazine may produce red-brown urine discoloration after contact with sodium hypochlorite bleach (e.g., in toilets cleaned with sodium hypochlorite contained in certain bleaches).

Serious blood dyscrasias have been reported very rarely with mesalazine. Hematological investigations should be performed if patients suffer from unexplained haemorrhages, bruises, purpura, anaemia, fever or pharyngolaryngeal pain. Salofalk rectal foam should be discontinued in case of suspected or confirmed blood dyscrasia.

Cardiac hypersensitivity reactions (myocarditis, and pericarditis) induced by mesalazine have been rarely reported. Salofalk rectal foam should then be discontinued immediately

Patients with pulmonary disease, in particular asthma, should be very carefully monitored during a course of treatment with mesalazine

Severe cutaneous adverse reactions

Severe cutaneous adverse reactions (SCARs), including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment.

Mesalazine should be discontinued, at the first appearance of signs and symptoms of severe skin reactions, such as skin rash, mucosal lesions, or any other sign of hypersensitivity.

Idiopathic intracranial hypertension

Idiopathic intracranial hypertension (pseudotumor cerebri) has been reported in patients receiving mesalazine. Patients should be warned for signs and symptoms of idiopathic intracranial hypertension, including severe or recurrent headache, visual disturbances or tinnitus. If idiopathic intracranial hypertension occurs, discontinuation of mesalazine should be considered.

Patients with a history of adverse drug reactions to preparations containing sulphasalazine should be kept under close medical surveillance on commencement of a course of treatment with mesalazine. Should Salofalk cause acute intolerance reactions such as abdominal cramps, acute abdominal pain, fever, severe headache and rash, therapy should be discontinued immediately.

This medicinal product contains 3.44 g propylene glycol in each actuation of Salofalk rectal foam. Propylene glycol may cause skin irritation.

This medicinal product contains sodium metabisulphite and cetostearyl alcohol.

Sodium metabisulphite may rarely cause severe hypersensitivity reactions and bronchospasm.

Cetostearyl alcohol may cause local skin reactions (e.g. contact dermatitis).

4.5. Interaction with other medicinal products and other forms of interaction

Specific interaction studies have not been performed.

In patients who are concomitantly treated with azathioprine, 6-mercaptopurine or thioguanine, a possible increase in the myelosuppressive effects of azathioprine, 6-mercaptopurine or thioguanine should be taken into account.

There is weak evidence that mesalazine might decrease the anticoagulant effect of warfarin.

4.6. Fertility, pregnancy and lactation

Pregnancy

There are no adequate data on the use of mesalazine in pregnant women.

However, data on a limited number of exposed pregnancies indicate no adverse effect of mesalazine on pregnancy or on the health of the foetus/newborn child. To date no other relevant epidemiologic data are available.

In one single case after long-term use of a high dose of mesalazine (2-4g, orally) during pregnancy, renal failure in a neonate was reported.

No animal studies with Salofalk rectal foam have been performed.

Animal studies on oral mesalazine do not indicate direct or indirect harmful effects with respect to pregnancy, embryonic/foetal development, parturition or postnatal development.

Salofalk rectal foam should only be used during pregnancy, if the potential benefit outweighs the possible risk.

Breastfeeding

N-acetyl-5-aminosalicylic acid and to a lesser degree mesalazine are excreted in breast milk. Only limited experience during lactation in women is available to date. Hypersensitivity reactions such as diarrhoea in the infant cannot be excluded.

Therefore, Salofalk rectal foam should only be used during breast-feeding, if the potential benefit outweighs the possible risk. If the infant develops diarrhoea, breast-feeding should be discontinued.

4.7. Effects on ability to drive and use machines

Mesalazine has no, or negligible, influence on the ability to drive and use machines.

4.8. Undesirable effects

System organ class

Frequency According to MedDRA Convention

Common

(≥1/100, <1/10)

Uncommon

(≥1/1,000, <1/100)

Rare

(≥1/10,000, <1/1,000)

Very rare

(<1/10,000)

Not known

(cannot be estimated from the available data)

General disorders and administration site conditions

Abdominal distension

Anal discomfort; application site irritation, painful rectal tenesmus

Blood and lymphatic system disorders

Altered blood counts (aplastic anaemia, agranulocytosis, pancytopenia, neutropenia, leukopenia, thrombocytopenia)

Nervous system disorders

Headaches, dizziness

Peripheral neuropathy

Idiopathic intracranial hypertension (see section 4.4)

Cardiac disorders

Myocarditis, pericarditis

Respiratory, thoracic and mediastinal disorders

Allergic and fibrotic lung reactions (including dyspnoea, cough, bronchospasm, alveolitis, pulmonary eosinophilia, lung infiltration, pneumonitis)

Gastrointestinal disorders

Abdominal pain, diarrhoea, flatulence, nausea, vomiting

Acute pancreatitis

Renal and urinary disorders

Impairment of renal function including acute and chronic interstitial nephritis and renal insufficiency

Nephrolithiasis*

Skin and subcutaneous tissue disorders

Rash, pruritus

Photosensitivity

Alopecia

Drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)

Musculoskeletal and connective tissue disorders

Myalgia, arthralgia

Immune system disorders

Hypersensitivity reactions such as allergic exanthema, drug fever, lupus erythematosus syndrome, pancolitis

Hepatobiliary disorders

Changes in liver function parameters (increase in transaminases and parameters of cholestasis), hepatitis, cholestatic hepatitis

Reproductive system disorders

Oligospermia (reversible)

* see section 4.4 for further information

Severe cutaneous adverse reactions (SCARs), including drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in association with mesalazine treatment (see section 4.4).

Photosensitivity

More severe reactions are reported in patients with pre-existing skin conditions such as atopic dermatitis and atopic eczema.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system, the Yellow Card Scheme, at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store

4.9. Overdose

There are rare data on overdosage (e.g. intended suicide with high oral doses of mesalazine), which do not indicate renal or hepatic toxicity. There is no specific antidote and treatment is symptomatic and supportive.

🇷🇴 Known in Romania as

Medicines sold in Romania with the same active substance: Cunoscut în România ca

  • SALOFALK 1 g prescriptionMESALAZINUM · rectal / vaginal
  • SALOFALK 250 mg prescriptionMESALAZINUM · rectal / vaginal
  • SALOFALK 4 g/60 ml prescriptionMESALAZINUM · rectal / vaginal
  • PENTASA 1000 mg prescriptionMESALAZINUM · rectal / vaginal

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →

🇵🇱 Known in Poland as

Medicines sold in Poland with the same active substance: W Polsce znany jako

  • PentasaMesalazinum · rectal / vaginal
  • SalofalkMesalazinum · rectal / vaginal
  • CrohnaxMesalazinum · rectal / vaginal
  • Salofalk 1 gMesalazinum · rectal / vaginal

Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →

💬 Ask about this leaflet

Ask anything about Salofalk 1g/actuation Rectal Foam. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →